AU2008289172B2 - Metabolomic profiling of prostate cancer - Google Patents

Metabolomic profiling of prostate cancer Download PDF

Info

Publication number
AU2008289172B2
AU2008289172B2 AU2008289172A AU2008289172A AU2008289172B2 AU 2008289172 B2 AU2008289172 B2 AU 2008289172B2 AU 2008289172 A AU2008289172 A AU 2008289172A AU 2008289172 A AU2008289172 A AU 2008289172A AU 2008289172 B2 AU2008289172 B2 AU 2008289172B2
Authority
AU
Australia
Prior art keywords
lcpos
sarcosine
cancer
metabolites
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008289172A
Other languages
English (en)
Other versions
AU2008289172A1 (en
Inventor
Christopher Beecher
Alvin Berger
Arul M. Chinnaiyan
Kay A. Lawton
Matthew W. Mitchell
Arun Sreekumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Metabolon Inc
Original Assignee
University of Michigan System
Metabolon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, Metabolon Inc filed Critical University of Michigan System
Publication of AU2008289172A1 publication Critical patent/AU2008289172A1/en
Application granted granted Critical
Publication of AU2008289172B2 publication Critical patent/AU2008289172B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
AU2008289172A 2007-08-16 2008-08-15 Metabolomic profiling of prostate cancer Active AU2008289172B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US95623907P 2007-08-16 2007-08-16
US60/956,239 2007-08-16
US7554008P 2008-06-25 2008-06-25
US61/075,540 2008-06-25
US13327908P 2008-06-27 2008-06-27
US61/133,279 2008-06-27
PCT/US2008/073318 WO2009026152A1 (en) 2007-08-16 2008-08-15 Metabolomic profiling of prostate cancer

Publications (2)

Publication Number Publication Date
AU2008289172A1 AU2008289172A1 (en) 2009-02-26
AU2008289172B2 true AU2008289172B2 (en) 2013-01-17

Family

ID=40363136

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008289172A Active AU2008289172B2 (en) 2007-08-16 2008-08-15 Metabolomic profiling of prostate cancer

Country Status (6)

Country Link
US (1) US20090047269A1 (enExample)
EP (2) EP2179292B1 (enExample)
JP (2) JP5406187B2 (enExample)
AU (1) AU2008289172B2 (enExample)
CA (1) CA2695674A1 (enExample)
WO (1) WO2009026152A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061899B1 (en) 2006-09-19 2012-08-29 Metabolon Inc. Biomarkers for prostate cancer and methods using the same
WO2009020521A2 (en) 2007-08-03 2009-02-12 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
JP5754137B2 (ja) * 2008-06-20 2015-07-29 味の素株式会社 前立腺癌の評価方法、前立腺癌評価装置、前立腺癌評価方法、前立腺癌評価プログラム、記録媒体、前立腺癌評価システム、および情報通信端末装置
PL2438445T3 (pl) * 2009-06-04 2014-12-31 Metanomics Health Gmbh Sposoby diagnozowania raków gruczołu krokowego
EP2488666A4 (en) * 2009-10-13 2013-05-29 Purdue Research Foundation BIOMARKERS AND IDENTIFICATION METHOD FOR THE EARLY DETECTION AND PREDICTION OF THE REPRESENTATION OF BREAST CANCER BY NMR
EP3438656A3 (en) * 2009-10-30 2019-05-01 Keio University Anticancer agent sensitivity-determining marker
JP2013515270A (ja) * 2009-12-22 2013-05-02 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌の代謝学的プロファイリング
WO2011088030A1 (en) * 2010-01-15 2011-07-21 Bryan William Jones Disease diagnosis and treatment using computational molecular phenotyping
EP2354794A1 (en) * 2010-01-29 2011-08-10 IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. Diagnosing prostate cancer relapse
JP2011247869A (ja) * 2010-04-27 2011-12-08 Kobe Univ メタボローム解析手法を用いた特定疾患の検査方法
WO2011146683A1 (en) * 2010-05-19 2011-11-24 Metabolon, Inc. Methods and reagents for metabolomics and histology in a biological sample and a kit for the same
CA2807811A1 (en) * 2010-07-28 2012-02-02 Metabolon Inc. Biomarkers for prostate cancer and methods using the same
EP2841948A1 (en) * 2012-04-27 2015-03-04 Eastern Virginia Medical School Quantitation of biomarkers for the detection of prostate cancer
WO2014074821A1 (en) * 2012-11-09 2014-05-15 Dana-Farber Cancer Institute, Inc. Metabolic profiling in tissue and serum is indicative of tumor differentiation in prostate cancer
WO2014089431A1 (en) * 2012-12-06 2014-06-12 Dana-Farber Cancer Institute, Inc. Metabolomic profiling defines oncogenes driving prostate tumors
KR101462206B1 (ko) 2013-06-26 2014-11-20 한국과학기술연구원 트립토판 대사 변화를 이용한 위암 진단용 기초 정보 제공 방법
JP6222629B2 (ja) * 2013-08-29 2017-11-01 花王株式会社 排尿障害のバイオマーカー
WO2015050366A1 (ko) * 2013-10-04 2015-04-09 주식회사 씨스퀘어 사르코신 대사산물 중 포름알데히드 또는 과산화물을 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단 방법
KR101838133B1 (ko) 2013-10-04 2018-03-14 주식회사 씨스퀘어 사르코신 대사산물 중 포름알데히드를 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단에 필요한 정보를 제공하는 방법
GB201408875D0 (en) 2014-05-19 2014-07-02 Cambridge Oncometrix Ltd Diagnostic method
WO2017210097A1 (en) 2016-06-02 2017-12-07 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
EP3490677A4 (en) * 2016-07-07 2020-05-13 Berg LLC LIPID, PROTEIN AND METABOLIC MARKERS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
KR101962882B1 (ko) 2017-06-01 2019-03-28 한국과학기술연구원 구연산염 검출 센서 및 이를 이용한 구연산염 검출 방법
CN114641690A (zh) * 2019-09-03 2022-06-17 远景科学私人有限公司 用于确认、检测和评估前列腺癌进展的方法以及相关治疗
WO2021138611A2 (en) * 2020-01-03 2021-07-08 Femtera Laboratories Reliable metabolite biomarkers for multiple urological cancers
CN115552025A (zh) * 2020-02-05 2022-12-30 克利夫兰诊所基金会 基于苯乙酰谷氨酰胺水平的疾病检测和治疗
CN113804901B (zh) * 2020-06-15 2023-06-23 南京市口腔医院 用于口腔鳞癌早期无创诊断的血清脂质标志物及其应用
KR102379017B1 (ko) * 2020-08-18 2022-03-28 서울대학교 산학협력단 13c 또는 2h 동위원소로 표지된 글라이신을 유효성분으로 포함하는 간암 진단용 조성물
CN113440533B (zh) * 2021-07-01 2022-02-01 江南大学 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用
CN115184478A (zh) * 2022-04-26 2022-10-14 沈阳药科大学 一种基于“纤维内衍生化”策略的血浆中70种氨基类物质的定量分析方法及其用途
KR102719659B1 (ko) * 2023-03-29 2024-10-17 경희대학교 산학협력단 퀴놀리늄계 화합물 및 이의 제조방법, 시트르산염 검출센서, 전립선암 진단센서 및 전립선암 진단방법
TW202528739A (zh) * 2023-09-05 2025-07-16 國立臺灣大學 用於前列腺癌的生物標記
GB2634269A (en) * 2023-10-04 2025-04-09 Aberystwyth Univ Biomarkers for prostate cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036691A2 (en) * 2006-09-19 2008-03-27 Metabolon, Inc. Biomarkers for prostate cancer and methods using the same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
FI875739A0 (fi) * 1986-04-28 1987-12-28 Boehringer Mannheim Gmbh Foerfarande och reagens foer paovisning av hjaertskador eller -sjukdomar.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5614396A (en) 1990-06-14 1997-03-25 Baylor College Of Medicine Methods for the genetic modification of endogenous genes in animal cells by homologous recombination
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
KR100334858B1 (ko) 1993-02-19 2006-01-27 니뽄 신야쿠 가부시키가이샤 핵산공중합체를함유하는의약조성물
WO1995034671A1 (en) 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
CA2203809C (en) 1994-10-28 2008-06-03 James M. Wilson Recombinant adenovirus and methods of use thereof
US5872154A (en) 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US6019978A (en) 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
US5994316A (en) 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
EP0914335A2 (en) 1996-03-15 1999-05-12 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1005546A2 (en) 1997-02-25 2000-06-07 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6080912A (en) 1997-03-20 2000-06-27 Wisconsin Alumni Research Foundation Methods for creating transgenic animals
ES2324503T3 (es) 1997-04-10 2009-08-07 Stichting Katholieke Universiteit University Medical Centre Nijmegen Pca3, genes pca3 y metodos de uso.
US5830730A (en) 1997-05-08 1998-11-03 The Regents Of The University Of California Enhanced adenovirus-assisted transfection composition and method
AU756549B2 (en) 1997-07-11 2003-01-16 Crucell Holland B.V. Interleukin-3 gene therapy for cancer
US5972639A (en) 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation
US6300136B1 (en) * 1997-09-03 2001-10-09 The Trustees Of The University Of Pennsylvania Methods for diagnosis and treatment of tumors in humans
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
JP2003528029A (ja) 1998-08-14 2003-09-24 アヴェンティス ファーマシューティカルズ インコーポレイテッド 遺伝子治療用のアデノウイルス配合物
WO2000012738A1 (en) 1998-08-27 2000-03-09 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
US6828429B1 (en) 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
WO2001078652A2 (en) * 2000-04-14 2001-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2001098754A1 (en) 2000-06-22 2001-12-27 Atto Instruments Llc High efficiency cell analysis system and high throughput drug screening system
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20030134677A1 (en) * 2001-09-27 2003-07-17 Salah Obied Method and apparatus for generating real-time embedded software for a chance game
US20070078093A1 (en) * 2003-10-16 2007-04-05 The Administrators Of The Tulane Educational Fund Methods and compositions for treating cancer
JP2005162714A (ja) * 2003-12-05 2005-06-23 Shoken Seika Kagi Kofun Yugenkoshi グリシンｎメチルトランスフェラーゼモノクローナル抗体およびその使用方法
US20060010505A1 (en) 2004-06-18 2006-01-12 Washington University High throughput cancer pharmaceutical screening using drosophila
US20070055456A1 (en) 2005-08-31 2007-03-08 Daniel Raftery NMR method for differentiating complex mixtures

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036691A2 (en) * 2006-09-19 2008-03-27 Metabolon, Inc. Biomarkers for prostate cancer and methods using the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REININGHAUS, F. et al. Proceedings of the American Association for Cancer Research. March 1992, Vol.33, page 201. *

Also Published As

Publication number Publication date
EP2179292A4 (en) 2010-08-25
EP2597464A3 (en) 2013-07-31
HK1143418A1 (en) 2010-12-31
JP2014041154A (ja) 2014-03-06
JP2010537170A (ja) 2010-12-02
EP2597464A2 (en) 2013-05-29
EP2179292B1 (en) 2012-11-28
CA2695674A1 (en) 2009-02-26
EP2179292A1 (en) 2010-04-28
US20090047269A1 (en) 2009-02-19
WO2009026152A1 (en) 2009-02-26
AU2008289172A1 (en) 2009-02-26
EP2597464B1 (en) 2015-02-25
JP5406187B2 (ja) 2014-02-05

Similar Documents

Publication Publication Date Title
AU2008289172B2 (en) Metabolomic profiling of prostate cancer
US20140051601A1 (en) Metabolomic profiling of cancer
Iglesias-Gato et al. The proteome of primary prostate cancer
Quezada et al. Omics-based biomarkers: current status and potential use in the clinic
Stockert et al. Predictive value of pseudouridine in prostate cancer
US20130261022A1 (en) Metabolomic profiling of prostate cancer
Xu et al. Quantitative proteomics study of breast cancer cell lines isolated from a single patient: discovery of TIMM17A as a marker for breast cancer
JP5297379B2 (ja) 前立腺癌のバイオマーカー及びそれを使用する方法
Lee et al. Altered proteome of extracellular vesicles derived from bladder cancer patients urine
Cui et al. Diagnostic and prognostic value of the cancer-testis antigen lactate dehydrogenase C4 in breast cancer
Jin et al. Protein modifications as potential biomarkers in breast cancer
Chen et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel‐assisted digestion and iTRAQ labeling mass spectrometry
Romano et al. Endometrial cancer diagnostic and prognostic algorithms based on proteomics, metabolomics, and clinical data: a systematic review
Ma et al. Mass spectrometry based translational proteomics for biomarker discovery and application in colorectal cancer
Liang et al. LcProt: Proteomics‐based identification of plasma biomarkers for lung cancer multievent, a multicentre study
Liu et al. Plasma exosomes contain protein biomarkers valuable for the diagnosis of lung cancer
Shekher et al. Association of altered metabolic profiles and long non-coding RNAs expression with disease severity in breast cancer patients: analysis by 1H NMR spectroscopy and RT-q-PCR
WO2016178236A1 (en) Methods and kits for breast cancer prognosis
HK1143418B (en) Metabolomic profiling of prostate cancer
Suehara et al. Discovery of biomarkers for osteosarcoma by proteomics approaches
Moshkovskii et al. OMICS for tumor biomarker research
Sousa MALDI-TOF MS-based urinary proteomic/peptidomic signature of breast cancer as innovative diagnostic approach
Wan et al. A high-performance metabolomic diagnostic panel for early-stage non-small cell lung cancer detection based on UPLC‒MS/MS
Davis The discovery and evaluation of metabolic and epigenetic biomarkers in the diagnosis of epithelial ovarian cancer
Qihan et al. FTSJ1 regulates tRNA 2ʹ-O-methyladenosine modification and suppresses the malignancy of NSCLC via inhibiting DRAM1 expression

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)